# A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

> **NCT07423117** · PHASE1 · NOT_YET_RECRUITING · sponsor: **IntoCell, Inc** · enrollment: 102 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Non-small Cell Lung Cancer
- Triple Negative Breast Cancer
- Metastatic Solid Tumor

## Interventions

- **DRUG:** ITC-6146RO

## Key facts

- **NCT ID:** NCT07423117
- **Lead sponsor:** IntoCell, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2027-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423117, "A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07423117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*